The enzyme D-glycerate dehydrogenase (D-GDH; EC 1.1.1.29), which is also believed to have glyoxylate reductase (GR; EC 1.1.1.26(79) activity, plays a role in serine catabolism and glyoxylate metabolism and deficiency of this enzyme is believed to be the cause of primary hyperoxaluria type 2 (PH2).
The primary hyperoxalurias (PH) are rare, autosomal recessive disorders characterized by raised plasma and urinary oxalate and differentiated by elevated glycolate excretion in most cases of the type I disease (PH I, alanine: glyoxylate aminotransferase deficiency) and of L-glycerate excretion in type 2 (PH2).1 Lglycerate is not normally detectable in urine, and its appearance in PH2 patients suggests a Correspondence: Dr G Rumsby. 104 failure to metabolize hydroxypyruvate by the usual metabolic route via D-glycerate, consistent with a lack of the enzyme D-glycerate dehydrogenase (D-GDH; EC 1.1.1.29). Peripheral blood lymphocytes from patients with primary hyperoxaluria type 2 (PH2) were subsequently found to lack D-GDH activity'< and D-GDH activity was absent or less than 5% of control values in liver from patients with PH2 J 5 adding further support for the lack of D-GDH as the metabolic defect underlying PH2. D-GDH is a cytosolic enzyme that catalyses the reduction of hydroxypyruvate to D-glycerate which is the second step in the degradative pathway of serine to gluconeogenic intermediates.1>-8 D-GDH also possesses glyoxylate reductase (GR; EC 1.1.1.26/79) activity? which catalyses the reduction of glyoxylate to glycolate and can thus contribute to the production of endogenous glycolate. In the absence of D-GDH, hydroxypyruvate is reduced to L-glycerate by L-Iactate dehydrogenase [(LDH) (EC 1.1.1.27)].1 The associated lack of GR activity is thought to prevent the reduction of glyoxylate to glycolate with the subsequent conversion of excess glyoxylate to oxalate by LDH accounting for the hyperoxaluria characteristic of PH2. I While the kinetics of the D-GDH and GR reactions have been determined in liver from cattle'?"? and rats.? little is known of the human enzyme and the assay currently used for the enzymatic diagnosis of PH2 in liver and lymphocytes is based on that established on beef liver." There is also little known with respect to the tissue distribution of D-GDH and consequently of the best means of treating this disease. We have therefore sought to characterize human D-GDH and present here the reaction kinetics and assay conditions for measurement of human D-GDH and GR and the tissue distribution of this enzyme.
MATERIALS AND METHODS

Human tissues
Human liver and kidney samples were from cadaveric organ donors free of prior known systemic disease. Tissue was stored at -70°C until analysis. Samples from patients with PH I, PH2, and other forms of hyperoxaluria were obtained from referrals to the University College Hospital's Primary Hyperoxaluria Service. Lymphocytes were obtained from healthy adult volunteers; fibroblasts and amniocytes from primary cultures.
Reagents
All chemicals were of analytical grade and were purchased from BDH (Poole, England) unless otherwise stated. P-Hydroxypyruvic acid lithium salt, glyoxylic acid, D( +) glyceric acid hemicalcium salt and hydrazine sulphate were purchased from Sigma (Poole, UK). Bovine serum albumin (BSA) 2 mg/rnl. and Cellu-Sep Regenerated Cellulose Tubular Membrane T2 (10 mm, molecular weight cut-off 8000-10 000)
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were obtained from Pierce Warriner (Warrington, UK). Folin-Ciocalteu reagent was obtained from Fisons (Loughborough, UK). J1-Nicotinamide adenine dinucleotide phosphate (oxidized form) monosodium salt (NADP) and J1-Nicotinamide-adenine-dinucleotide phosphate (reduced form) tetrasodium salt (NADPH) were purchased from Melford Laboratories (St Albans, UK). Phosphate buffer was prepared from equimolar solutions of di-potassium hydrogen orthophosphate and potassium dihydrogen orthophosphate. All reagents were prepared in double distilled deionized water. With the exception of NADPH and NADP which were prepared on the day of use and protected from light, all reagents were stable for at least 1 month when stored in aliquots at -20°C.
Sonication of biopsy material
All procedures were carried out at 4°C. The biopsy material was suspended in a sonication medium containing 240 mmol/L sucrose in 100rnmol/L potassium phosphate buffer pH 8, aiming for a final suspension of 2% w]». The suspended tissue was disrupted with four lOs bursts using a Microson XL sonicator with 20 s intervals between bursts. The non-suspended fibrous material was removed by centrifuging at 2000 g for 10 minutes. The resulting supernatant was dialysed overnight against 50mmol/L potassium phosphate buffer pH 7 with 0·1 mmol/L EDTA. The dialysate was centrifuged again at 12000 g for 15min and the supernatant analysed for D-GDH and GR activity. Protein was measured using the procedure of Lowry!" using bovine serum albumin as standard.
Enzyme assays
The initial conditions were obtained from Danpure.P Modifications were made after conducting kinetic analyses and pH optima studies. All the reactions were carried out in duplicate and the change in absorbance at 340 nm read against a tissue blank using a double beam spectrophotometer at 37°C. In each case the reaction was started by the addition of the non-nucleotide substrate (Dglycerate and hydroxypyruvate for the D-GDH reverse and forward reactions respectively and glyoxylate for the GR reaction). Enzyme activity was calculated as nmoles of NADPH oxidized or formed per minute; the specific activity was calculated as nmol per min per mg protein.
Determination of the optimal pllfor the enzyme assays
The pH of the assay buffer was varied from 5·8 to 7·8 for the D-GDH forward reaction, from 7-4 to 9·0 for the D-GDH reverse reaction and from 6-4 to 8·0 for the GR reaction.
Determination of Km Km was determined from a Hanes-Woolf plot of [substrate'[/velocity against [substrate]
where the X-axis intercept is -Km and the y axis intercept Km/Vmax. 16 Final assay conditions Reaction conditions for D-GDH and GR assays on the Cobas Bio centrifugal analyser (Roche Diagnostic System, Welwyn Garden City, UK) are given in Table I .
RESULTS
pH optima
Maximal activity was observed for the D-GDH forward reaction at pH 6·0 falling rapidly with increasing pH to approximately 10% of maximum at pH 7·4. The choice of pH 6·0 for this reaction did have the disadvantage that nonenzymatic degradation of NADPH occurred, but the effect of this was minimized by inclusion of a tissue blank. The D-GDH reverse reaction was less affected by variations of pH but activity was highest between pH 8-9. A pH of 8·0 was selected for the assay. Maximal GR activity was observed at pH 7·6.
TABLE I. Reaction condition for determination of Dglycerate dehydrogenase (D-GDH) and glyoxylate reductase (GR) assays on Cobas Bio analyser
Determination of the Km for the substrates in the D-GDH and GR reactions The results obtained and conditions chosen for the subsequent assays are summarized in Table  2 . For reasons of poor solubility or inhibition it was not possible to use saturating concentrations of all substrates and therefore the calculated Km is only the apparent Km for the reaction. The NADPH concentration is a limiting factor for both the D-GDH and GR assays. Concentrations of greater than 0·6 rnrnol/L exceed the linearity of most spectrophotometers and in the GR assay concentrations of greater than 0·8 mmol/L were inhibitory. Theoretically, the reaction velocity of the GR assay could be increased from O· 57 Vmax to 0·62 Vmax by using a higher glyoxylate concentration (25 mmol/L).
Although this was not done for the present study, it should be considered for future studies measuring GR activity in lymphocytes. The reverse D-GDH assay was not subsequently utilized for diagnostic purposes because of formation of an insoluble precipitate at high glycerate concentrations and the very low activity found in this direction. Both D-GDH (forward) and GR reactions were subsequently adapted for the Cobas Bio centrifugal analyser (see Table I ).
Limit of linearity of the D-GDH and GR reactions
Using the automated analysis of the Cobas Bio (see Table I ), the D-GDH (forward) reaction was linear to an activity of 1400 nmol per min per mg protein (equivalent to 42 J.lg liver protein per reaction). The linearity of the GR reaction was not exceeded at 429 nmol per min per mg protein (63 ug liver protein per reaction), approximately 2·5 times the activity expected with a normal liver sample.
*D-GDH assay: 1·2mmoljL NADPH in 0·1 M hosphate buffer, pH 6·0. GR assay: l-Zrnmol/L NADPH in 0·1M phosphate buffer, pH 7·6. tD-GDH assay: 50mmoljL hydroxypyruvate. G R assay: 50mmoljL glyoxylate. 
Intra-assay variation
The intra-assay variation of the Cobas assay was estimated by determining the coefficient of variation (CV) for both D-GDH (forward) and GR assays in 10 replicates. The CV was 0·8% and 2·4% at activities of 1037 and 333 nmol per min per mg protein, respectively, for the 0-GDH (forward) reaction. For the GR reaction the CVs were 4·7% and 7·3% at activities of 153 and 44nmol per min mg protein, respectively.
Minimum detectable activity
The minimum detectable activity, taken as the mean plus 3 standard deviations of a suitable blank, was calculated by taking 10 measurements of a heat-treated sample (70°C for 40 min) and reading it against a similarly treated, tissue 
Stability of sonicates
There was no loss of either GR or D-GDH (forward) activity from a 2% (wjv) liver lysate over a period of I month when stored at -70°C.
Reference range and tissue distribution of D-GDH and GR
The tissue distribution of D-GDH (forward) and GR are shown in Fig. I(a) Fig. l(b) ]. D-GDH (forward) and GR activity in livers from 12 patients with primary hyperoxaluria type I (PH I) ranged from 387-950 nmol per min per mg protein and 92-296 nmol per min per mg protein, respectively, that is, within the reference range for normal livers. Three liver samples from PH2 patients previously diagnosed by the finding of raised urinary L-glycerate were analysed. Significant D-GDH (forward) activity was present although in all three cases it was below the normal range (342, 230 and 142, respectively) but GR activity in the same samples was either very low (18, n = 2) or undetectable (n= 1). Interestingly, lymphocyte D-GDH (forward) from two PH2 patients showed activity within the normal range [ Fig.  I(a) ]. GR in these samples was undetectable although it must be remembered that GR activity is very low in normal lymphocytes.
DISCUSSION
The measurement of D-GDH has been suggested to provide a definitive diagnosis of PH2 in a subject with hyperoxaluria and L-glycericaciduria. However, the assays in use are based on conditions set up for measurement of this enzyme in other species. As part of a project to define the molecular nature of PH2 we have sought to characterize the human enzyme and to develop sensitive assays for its measurement. Assay conditions were selected to maximize sensitivity which required the use of nonphysiological pH.
A number of problems were encountered in assay development including the non-enzymatic oxidation of NADPH in the presence of phosphate buffer at acid pH. 17 Replacement of the phosphate buffer in the D-GDH forward reaction with citrate at pH 6 was unsuccessful either because citrate inhibits the reaction or more probably because phosphate enhances D-GDH activity." The reverse D-GDH reaction (glycerate to hydroxypyruvate) previously used by other groups-' was not practical for two reasons. First, the addition of D-glycerate to a liver sonicate was followed by formation of a visible precipitate becoming more prominent and occurring faster with increasing concentrations of D-glycerate. Secondly, the activity of this, non-physiological reaction, was extremely low and undetectable in 2% (w/v) sonicates.
It was not possible to use optimal substrate concentrations for the measurement of GR because NADPH at concentrations greater than 0·8 mmol/L was found to inhibit the reaction and the absorbance of NADPH at concentrations greater than 0·6 rnrnol/L exceeds the linearity of most spectrophotometers. These restrictions limited the range of the GR reaction in which the NADPH concentration was only 1·8 times Km. In practice, however, the activity limit per assay is unlikely to be exceeded in a routine assay. D-GDH (forward) and GR activity was determined in a number of livers from normal subjects in addition to samples from patients with PH 1 and PH2. The samples from patients with PHI had activities within the reference range whereas those from three subjects with PH2 had measureable D-GDH (forward) activity although in all cases below the reference range. GR in the PH2liver samples was less than 15% of the median.
Tissue distribution studies yielded some interesting if rather unexpected findings. D-GDH (forward) activity was found in all tissues tested, that is liver, kidney, lymphocyte and fibroblast [ Fig. lea) ]. GR activity on the other hand was present in liver but Ann cu« Biochem 1998: 35 substantially less was present in kidney, lymphocytes and fibroblasts [ Fig. l(b) ]. Lymphocytes from two PH2 patients had D-GDH (forward) activity within the reference range [ Fig. lea) ] but undetectable GR [ Fig. l(b) ]. Based on the results presented in this paper, we propose that there are at least two enzymes with D-GDH (forward) activity, only one of which also has the ability to reduce glyoxylate. The latter is predominantly hepatic in origin with lesser amounts in kidney and lymphocytes. These results are consistent with the finding that both D-GDH and GR activity co-purify from human (Giafi and Rumsby, unpublished data) and rat liver? and reduced GR and D-GDH activity has been documented in liver from patients with PH2 in this study and those of others.l" These results could also be explained by the presence of an inhibitor of G R activity in the different tissues, although we have no evidence to support this theory in vitro.
The observed tissue distribution has significance for the diagnosis and treatment of PH2. The accumulation of L-glycerate as a result of the action of lactate dehydrogenase on excess hydroxypyruvate probably has little pathological consequence as it is relatively soluble. Deficient GR activity however, with the subsequent increase of oxalate production in vivo, will lead to oxalate accumulation and precipitation. From our analyses, GR expression is highest in the liver and thus, to prevent the endogenous overproduction of oxalate, the definitive treatment of PH2 would appear to be liver transplantation as recommended for PH I.
Our results suggest that for the diagnosis of PH2, the measurement of both GR and D-GDH (forward) is preferable to D-GDH alone. While this approach requires a liver biopsy, these assays can be measured in conjunction with a semi-automated assay for alanine: glyoxylate aminotransferase'? and thus a definitive diagnosis of either PHI or PH2 can be made on a single, needle liver biopsy.
